Status:
COMPLETED
Testing a Causal Model of Cognitive Control Deficits in Posttraumatic Stress Disorder (PTSD)
Lead Sponsor:
Florida State University
Conditions:
PTSD
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Testing a Causal Model of Cognitive Control Deficits in Posttraumatic Stress Disorder (PTSD)
Detailed Description
The purpose of the present study is to examine the effects of transcranial magnetic stimulation (TMS) on cognitive control among individuals with posttraumatic stress disorder (PTSD).
Eligibility Criteria
Inclusion
- Over 18 years of age
- Endorse lifetime exposure to at least one Criterion A traumatic event
- Report clinically significant posttraumatic stress disorder (PTSD) symptoms (score of ≥ 33 on the PTSD Checklist for DSM-5 \[PCL-5\]).
Exclusion
- Endorse medical contraindication for neuromodulation (e.g., ferrous metal in head, seizure disorder, brain tumor, stroke, aneurysm, multiple sclerosis, etc.)
- Report an unstable medical condition or any current medical condition that precludes safe participation in the trial (e.g., unstable metabolic abnormality, unstable angina, etc.)
- Report any history or diagnosis of dementia or other cognitive disorder, which may interfere with engagement
- Report any history or diagnosis of Severe Traumatic Brain Injury
- Report any history or diagnosis of Schizophrenia, Schizoaffective Disorder, Delusional Disorder or other psychotic illness, which precludes safe participation in the trial
- Report a primary obsessive-compulsive disorder (OCD) diagnosis
- Report an active substance use disorder (within last 3 months) or any current substance use that precludes safe participation in the trial
- Report suicide risk that precludes safe participation in the trial, defined as clinical impression that the participant is at significant risk for suicide (i.e., greater than moderate level of suicide risk, in accordance with the Joiner et al. (1999) suicide risk framework)
- Report an inability to stop taking any medication that significantly lowers the seizure threshold (e.g., tricyclic antidepressants, clozapine, etc.)
- Report a current, planned, or suspected pregnancy
Key Trial Info
Start Date :
September 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 3 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06016673
Start Date
September 13 2023
End Date
February 3 2024
Last Update
April 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida State University College of Medicine
Tallahassee, Florida, United States, 32306